Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis

Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis
Cellceutix has initiated the dose escalation of brilacidin (PMX-30063) in the second cohort of patients enrolled in a Phase 2 clinical trial evaluating the drug candidate for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS), two types of ulcerative colitis (UC). UP is a mucosal inflammatory bowel disease of unknown cause involving only the rectum. UP evolves to UPS when both the rectum and the distal colon are involved. Brilacidin is the company’s lead drug candidate modeled after host defense proteins (HDPs), the front-line of defense in the immune system. It's a small synthetic molecule that kills pathogens and functions in a robust immuno
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *